Dr. Sidhartha R. Sinha, an Indian American Assistant Professor of Medicine at Stanford University, has won the 2026 Sherman Emerging Leader Prize “for challenging conventional thinking and pioneering new solutions to address patients’ unmet needs.”
The $25,000 prize is awarded to IBD clinicians, surgeons, researchers, academics, or physician assistants, who, while early in their careers, have contributed to an advancement and show great promise for significant future contributions.
Sinha, Director of Digital Health and Innovation at Stanford University School of Medicine, is one of three physician scientists to receive the 2026 Sherman Prizes from Bruce and Cynthia Sherman Charitable Foundation.
The prizes recognize three physician-scientists who are dedicated to improving outcomes for patients with Crohn’s disease (CD) and ulcerative colitis, collectively known as inflammatory bowel diseases (IBD), according to a media release.
Read: Aeris names Indian American techie Suresh Sathyamurthy CMO (September 4, 2026)
“Their remarkable work represents the extraordinary breadth of what is possible in IBD, from transforming patient care and advancing treatment to making discoveries that open new possibilities for the future,” said Bruce and Cynthia Sherman, the founders of the Sherman Prize.
“Dr. Sinha exemplifies the talent and ambition of a remarkable new generation of investigators, giving us tremendous confidence in the future of IBD research and care,” said Dr. Corey A. Siegel, 2026 Selection Committee Chair and 2023 Sherman Prize recipient,
Dr. Sinha’s career is defined by a rare curiosity about problems others may overlook and a determination to pursue them wherever they lead. Guided by patients’ unmet needs, he looks beyond conventional approaches, connecting ideas, expertise and disciplines from unexpected places to find better answers, according to the citation.
As a first-year GI fellow, Dr. Sinha saw an opportunity to solve a longstanding challenge for a patient in his 90s with ulcerative colitis whose existing treatments were resulting in severe bone loss and other side effects.
He assembled a team, including Stanford material scientists, to develop a groundbreaking thermosensitive delivery system that targets treatment directly to affected tissue—an innovation published in Gastroenterology that has advanced to human trials.
It is this rare ability to envision what does not yet exist, find a way to build it, and bring together the expertise to make it possible that sets Dr. Sinha apart.
Read: Aeris names Indian American techie Suresh Sathyamurthy CMO (September 4, 2026)
He likewise established the use of a swallowable capsule technology to assess the microbiome and metabolome within the small intestine in patients with IBD, overcoming a major limitation of traditional stool-based research; this work earned a 2024 Rainin Foundation Innovator Award.
Dr. Sinha has brought the same imagination to some of IBD’s most difficult challenges. His research is uncovering the potential of widely used statins to prevent or slow fibrosis and disease progression, taking those findings from large-scale retrospective studies to two prospective clinical trials designed to determine both their effectiveness and which patients are most likely to benefit.
He is also rethinking how disease can be monitored, demonstrating that molecules in exhaled breath condensate can distinguish active from inactive ulcerative colitis and potentially outperform conventional blood and stool biomarkers in discovery and validation cohorts. The work could ultimately give patients a simpler, less invasive way to track disease activity and response to treatment.
The Prize recipients will be recognized at the Advances in IBD (AIBD) conference in Orlando, Florida, on Dec. 8 where a tribute film for each honoree will premiere.